**The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: a modelling study**

**Authors**

Allison Portnoy, ScD[1], Rebecca A. Clark, MSc[2-4], Matthew Quaife, PhD[2-4], Chathika K. Weerasuriya, PhD[2-4], Christinah Mukandavire, PhD[2-4], Roel Bakker, PhD[2-5], Arminder K. Deol, PhD[2-4,6], Shelly Malhotra, PhD[7,8], Nebiat Gebreselassie, PhD[9], Matteo Zignol, MD[9], So Yoon Sim, MA, MSPH[10], Raymond C.W. Hutubessy, PhD[10], Inés Garcia Baena, MSc[9], Nobuyuki Nishikiori, PhD[9], Mark Jit, PhD[3,4,11], Richard G. White, PhD[2-4,*], Nicolas A. Menzies, PhD[1,12]*

* Co-senior authors

**Affiliations**

1. Center for Health Decision Science, Harvard T.H. Chan School of Public Health, Boston, MA, USA
2. TB Modelling Group, London School of Hygiene and Tropical Medicine, London, UK
3. Centre for the Mathematical Modelling of Infectious Diseases, London School of Hygiene and Tropical Medicine, London, UK
4. Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK
5. KNCV Tuberculosis Foundation, The Hague, Netherlands
6. Coalition for Epidemic Preparedness Innovations, London, UK
7. Market Access, Global Alliance for TB Drug Development, New York, New York, USA
8. Global Access, International AIDS Vaccine Initiative, New York, New York, USA
9. Global TB Programme, World Health Organization, Geneva, Switzerland
10. Department of Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland
11. School of Public Health, University of Hong Kong, Hong Kong SAR, China
12. Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, MA, USA

**Corresponding Author**: Allison Portnoy, Center for Health Decision Science, Harvard T.H. Chan School of Public Health, 718 Huntington Avenue 2nd Floor, Boston MA 02115, USA. Phone: +1(617) 432-2019. Email: aportnoy@mail.harvard.edu.

Acknowledgements: The views expressed are those of the authors and do not necessarily represent the views of their respective organizations.

**Abstract**

*Background:* Tuberculosis (TB) is preventable and curable but eliminating it has proven challenging. Safe and effective TB vaccines that can rapidly reduce disease burden are essential for achieving TB elimination. We assessed future costs, cost-savings, and cost-effectiveness of introducing novel TB vaccines in low- and middle-income countries (LMICs) for a range of product characteristics and delivery strategies.

*Methods and Findings:* We developed a system of epidemiological and economic models, calibrated to demographic, epidemiological, and health service data in 105 LMICs. For each country, we assessed the likely future course of TB-related outcomes under several vaccine introduction scenarios, compared to a 'no-new-vaccine' counterfactual. Key economic inputs were derived from the Global Health Cost Consortium, WHO patient cost surveys, and the published literature. We estimated the incremental impact of vaccine introduction for a range of health and economic outcomes. In the base-case, we assumed a vaccine price of $4.60, and used a 1x per-capita GDP cost-effectiveness threshold (both varied in sensitivity analyses). Vaccine introduction was estimated to require substantial near-term resources, offset by future cost-savings from averted TB burden. From a health system perspective, adolescent/adult vaccination was cost-effective in 64 of 105 LMICs. From a societal perspective (including productivity gains and averted patient costs), adolescent/adult vaccination was projected to be cost-effective in 73 of 105 LMICs and cost-saving in 58 of 105 LMICs, including 96% of countries with higher TB burden. When considering the monetized value of health gains, we estimated that introduction of an adolescent/adult vaccine could produce $283–474 billion in economic benefits by 2050. Limited data availability required assumptions and extrapolations that may omit important country-level heterogeneity in epidemiology and costs.

*Conclusions:* TB vaccination would be highly impactful and cost-effective in most LMICs. Further efforts are needed for future development, adoption, and implementation of novel TB vaccines.

*Funding:* World Health Organization (2020/985800-0)

**Author summary**

*Why was this study done?*

- Previous studies have highlighted the economic impact of tuberculosis (TB) disease and mortality, and the potential economic impact that novel TB vaccines could have on reducing this burden in specific low- and middle-income countries (LMICs).
- The cost and cost-effectiveness of novel TB vaccines, which depend on vaccine price and delivery strategy that may vary by country, are needed by vaccine developers, manufacturers, and potential purchasers to guide investment decisions.
- No modelling studies have estimated the cost and cost-effectiveness of novel TB vaccine products with country-specific assumptions for medical and non-medical costs, indirect costs, vaccine delivery costs, and delivery strategies across a wide range of LMICs.

*What did the researchers do and find?*

- We estimated the costs, cost-effectiveness, and incremental net monetary benefit of TB vaccine introduction from both the health system and societal perspective, in order to inform global-level decision-making for novel TB vaccine investment and introduction.
- Using mathematical and economic models, we assessed scenarios for the introduction of novel TB vaccines with a wide range of characteristics and a diverse set of health and economic outcomes, including country-specific introduction years from 2028–2047.
- Our analysis projected that an effective new TB vaccine could offer large potential health and economic benefits over 2028–2050. From a societal perspective, vaccination was projected to be cost-effective in 74 LMICs compared to a 1x per-capita gross domestic product threshold.
- When considering the monetized value of health gains, we estimated that introduction of an adolescent/adult TB vaccine could produce $283–474 billion in health and economic benefits by 2050, with greater benefits in LMICs with elevated TB incidence.

*What do these findings mean?*

- Introduction of a new TB vaccine was found to be impactful and cost-effective for a range of assumptions on vaccine price and delivery strategies, with aggregate health and economic benefits of similar scale to the most influential health interventions in LMIC settings in recent years.
- The results of these analyses can be used by global and country stakeholders to inform TB vaccine policy and introduction preparedness, as well as decision-making around future development, adoption, and implementation of novel TB vaccines.

# 1 Background

Tuberculosis (TB) is one of the world's leading causes of infectious disease death [1]. It remains

the leading cause of death for people living with HIV and a major contributor to antimicrobial-

resistance-related deaths. The COVID-19 pandemic has reversed years of progress in providing

TB services and, consequently, the number of people who died from TB increased to 1.5 million

in 2020 [1].

The World Health Organization (WHO)'s End TB Strategy targets a 90% reduction in TB

mortality and 80% decline in TB incidence by 2030, compared to 2015 [2]. Achieving these

targets will require a comprehensive multisectoral response, along with transformational new

tools. The cost of not meeting the End TB Targets by 2030 and facing the excess deaths resulting

from COVID-19-related disruptions to TB services may translate into 31.8 million TB deaths

globally corresponding to an economic loss of $17.5 trillion between 2020 and 2050 [3].

Developing new safe, affordable, and effective TB vaccines is critical for achieving these targets.

While promising candidates exist (for example, the M72/AS01$_E$ candidate vaccine [4]), limited

market incentives to invest in TB prevention has delayed the development of novel TB vaccines.

The WHO promotes the Full Value of Vaccines Assessment framework to improve decision-

making around vaccine development and use [5, 6]. As part of a Full Value of Vaccines

Assessment of novel TB vaccines, we estimated the costs, cost-effectiveness, and net monetary

benefit of TB vaccine introduction, from health system and societal perspectives, to inform

global-level decision-making for novel TB vaccine investment and introduction [5, 6].

**Methods**

*Analytic overview*

We estimated a range of outcomes quantifying the health and economic impact of new vaccine introduction for affected countries. To do so, we used linked epidemiological and economic models to project changes in healthcare utilization, health outcomes, and healthcare costs for various vaccine introduction scenarios compared to a 'no-new-vaccine' counterfactual. (Full epidemiological model details have been previously reported by Clark and colleagues [7], and are briefly described in Appendix S1. Any changes to the analysis that were required are also described; no prospective analysis plan was developed.) We estimated outcomes for each of 105 low- and middle-income countries (LMICs) over a 2028–2050 evaluation period (Appendix S2). We summarized results as the incremental costs, cost-effectiveness, and incremental net monetary benefits of vaccine introduction. Results are presented for a range of analytic assumptions and introduction scenarios, organized by major country groupings (WHO region, World Bank income level [8], and WHO high-TB burden grouping [9]).

*Vaccination scenarios*

We constructed a 'no-new-vaccine' baseline with current TB interventions continuing into the future at current levels. Compared to this baseline, we evaluated two different vaccine product profiles: an infant 'pre-infection' prevention of disease vaccine (i.e., efficacious for individuals uninfected at time of vaccination) with 80% efficacy targeting neonates, and an adolescent/adult 'pre- and post-infection' prevention of disease vaccine (i.e., efficacious in all individuals aside from those with active TB disease at time of vaccination) with 50% efficacy, based on WHO Preferred Product Characteristics for New Tuberculosis Vaccines [10]. For both vaccine product

profiles, we assumed an average ten-year duration of protection, with exponential waning. We

assumed the infant vaccine would be delivered through the routine vaccination program, with

vaccine delivery at fixed sites following a standard dosing schedule. We assumed the

adolescent/adult vaccine would be delivered through routine vaccination of nine-year-olds plus a

one-time vaccination campaign for ages 10+. In the base-case scenario, we assumed countries

would achieve linear scale-up to a specified coverage over five years. Based on consultation with

global stakeholders, we assumed a coverage target of 85% for the infant vaccine (average

coverage of diphtheria-tetanus-pertussis third dose for LMICs [11]), 80% for routine delivery of

adolescent/adult vaccine, and 70% of the adolescent/adult vaccination campaign [12]. We

selected 2028 as the earliest country-specific introduction year to align with anticipated product

availability following TB vaccine candidate trial completion. We assumed country-specific

introduction years from 2028–2047, determined based on indicators for disease burden,

immunization capacity, classification of the country as an "early adopter/leader," lack of

regulatory barriers, and commercial prioritization [7]. Further details regarding vaccination

scenarios are provided in the appendix.

*Epidemiological outcomes and health service utilization*

We projected future TB epidemiology and health service utilization using an age-structured TB

transmission model calibrated to reported demography, TB burden estimates, and TB service

utilization in each modelled country [7]. Out of 135 LMICs [8], we excluded 20 due to lack of

critical calibration data and 10 due to unsuccessful calibration results (details provided in

Appendix S1). We analyzed the remaining 105 countries (Appendix S2), representing 93.3% of

global TB burden [13]. In countries in which the proportion of TB cases among people living

with HIV was greater than or equal to 15%, and the HIV prevalence in the country was greater

than 1%, the model included the effects of HIV and antiretroviral therapy (ART) on TB infection

and progression risks (Appendix S1). Using this model, we estimated changes in TB

epidemiology and related service utilization for each modelled scenario.

*Summary health outcomes*

We estimated disability-adjusted life-years (DALYs) averted to quantify the health gains

achieved by vaccination. To calculate years lost due to disability (YLDs), we assigned each

modelled health state a disability weight from the Global Burden of Disease classification system

(Appendix S3) [14]. For each scenario and year, total YLDs were calculated by summing life-

years lived across all health states, weighted by the disability weight for each state. For each

scenario and year, years of life lost were calculated by multiplying deaths at each year of age by

reference life expectancy at that age [15], and summing across all ages.

*Cost outcomes*

We estimated the costs of vaccine introduction, as well as changes in the costs of other health

services (TB care, HIV care) by multiplying health service volume indicators (vaccines

delivered, TB cases diagnosed and treated, ART patient-years) by country-specific unit costs.

Diagnostics costs for drug-susceptible (DS) and rifampicin-resistant (RR) TB were obtained

from published literature as average values for each country income level [16], which were

assigned to each LMIC in the associated country income level grouping [8]. Unit costs for TB

treatment were calculated as an average of country-level DS-TB [17] and income-level RR-TB

[16, 18] treatment costs, weighted by country-level RR-TB prevalence [1].

For ART costs, direct non-medical costs (travel, accommodation, food, nutritional supplements)

to the patient, and productivity costs (income loss experienced by patients during TB care), we

derived unit costs by extrapolating estimates reported by the Global Health Cost Consortium [19]

(sample size = 39) and WHO patient cost surveys (sample size = 20) [20, 21] with meta-

regression models for the respective outcomes specified as generalized linear regression models

(GLMs), assuming a Gamma distributed outcome, a log link function, and gross domestic

product (GDP) per capita as the predictor [22]. The previous unit costs were inflated to 2020

values in local currency using the country consumer price index [23], and converted to 2020 US

dollars using market exchange rates [24].

Productivity costs due to premature death were estimated as the incremental number of life-years

gained under a given vaccination scenario, multiplied by 2020 per-capita GDP as an

approximation of income.

As the per-dose cost for novel TB vaccines is unclear while products are still under development,

the base-case used an LMIC price of human papillomavirus (HPV) vaccine ($4.60) for a novel

vaccine proxy with an injection supply cost per dose of $0.11 and 5% wastage [25, 26]. Country-

specific vaccine delivery costs were based on a meta-analysis of childhood [27] and HPV

vaccine delivery unit costs for the infant and adolescent/adult vaccines, respectively, plus

additional one-time vaccine introduction costs ($0.65 and $2.40 per targeted individual in the

first year of introduction for infant and adolescent/adult vaccines, respectively) [28]. Costs are

reported in 2020 US dollars.

*Cost-effectiveness analysis*

Incremental cost-effectiveness ratios (ICERs) were calculated from health system and societal

perspectives, with a 3% discount rate, across the 2028–2050 evaluation period. We also reported

a specification in which costs are discounted but not health outcomes. The health system

perspective considered costs of vaccine introduction, plus the costs of TB and HIV services

indirectly affected by vaccine introduction. The societal perspective additionally included patient

non-medical and productivity costs. ICERs were compared to a range of country-specific cost-

effectiveness thresholds to reflect the lack of consensus for a single threshold, including

multiples of per-capita GDP [29] (assuming 1x per-capita GDP as a proxy for willingness to pay

in the base-case), recent estimates of the opportunity cost of healthcare spending [30, 31], and

the WHO's universal "Best Buy" threshold of $100 per DALY averted. This study is reported as

per the Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022)

statement (Appendix S4) [32].

*Return on investment*

We quantified the return on investment as the incremental net monetary benefit (iNMB) from the

societal perspective of each vaccine scenario compared to baseline for a range of willingness-to-

pay thresholds [29-31]. iNMB was calculated as the sum of monetized health gains (DALYs

averted multiplied by the estimated willingness-to-pay per DALY averted) minus incremental

costs. We estimated the market size for each vaccine product profile, summing all individuals

across 2028–2050 who were vaccinated in the model in the base-case scenario in countries in

which the vaccine was cost-effective (ICER less than per-capita GDP). We also estimated market

size based on countries in which vaccination was cost-saving under the societal perspective.

*Statistical analysis*

We explored estimation uncertainty using a 2$^{nd}$-order Monte Carlo simulation [33]. We

constructed probability distributions representing uncertainty in economic inputs and disability

weights, specified as Gamma distributions for parameters defined over [0, ∞], and Beta

distributions for parameters defined over [0, 1]. For each parameter the distribution mean was set

equal to the point estimate, and the dispersion was set so an equal-tailed 95% interval reproduced

the reported interval width. For parameters estimated from a meta-regression model (ART costs,

patient costs) we simulated parameter values from each fitted regression model. We drew 1000

random values for each uncertain parameter. We represented uncertainty in healthcare utilization

and epidemiological outcomes (counts of each outcome by scenario, year, and population

stratum) using 1000 results sets from the transmission-dynamic model. This analysis generated

1000 estimates for each outcome of interest, which we summarized as equal-tailed 95%

uncertainty intervals.

*Sensitivity analysis*

Compared to the base-case coverage targets (85%, 80%, 70% for routine infant vaccine delivery,

routine adolescent vaccine delivery, and campaign adolescent/adult vaccine delivery,

respectively), we examined a low-coverage scenario (75%, 70%, and 50%, respectively) and a

high-coverage scenario (95%, 90%, and 90%, respectively).

We examined two alternative vaccine delivery scenarios. First, we modelled an accelerated

scale-up scenario in which all countries introduced vaccination in 2025 and achieved

instantaneous scale-up to the specified coverage target. Second, we modelled a routine-only

scenario which removed the one-time campaign-delivery component of the adolescent/adult

base-case scenario.

We examined three alternative vaccine price scenarios, including scenarios in which the base-

case vaccine price of $4.60 was both halved ($2.30) and doubled ($9.20), respectively. A third

scenario examined high-middle-tier vaccine pricing, with higher prices for middle-income

countries based on UNICEF vaccine pricing data ($10.25 for non-Gavi countries with gross

national income (GNI) per capita less than $3,995 and $14.14 for non-Gavi countries with GNI

per capita greater than $3,995; Appendix S2) [25].

Compared to the base-case scenario assuming one vaccine dose, we estimated results assuming

that two vaccine doses were required to achieve the same level of efficacy, i.e., a full vaccination

course required 2x the base-case vaccine price of $4.60 and 2x the delivery cost.

We also estimated results with an alternative set of assumptions about TB incidence trends in the

no-new-vaccine baseline, with incidence assumed to decline more rapidly through the scale-up

of existing preventive treatment and case detection, meeting the 2025 'End TB' incidence

reduction target without introduction of a new vaccine [2].

Compared to the base-case assumption of ten-year duration of protection, we also examined

lifelong duration of protection conferred by vaccination.

Finally, compared to the base-case assumption of 50% efficacy for the adolescent/adult vaccine,

we also examined 75% efficacy conferred by this vaccine.

**Results**

*Costs and cost-effectiveness analysis*

A summary of the unit costs by country income level is provided in Table 1. In the no-new-

vaccine baseline, over 2028–2050, total undiscounted (i.e., without a 3% annual discount rate)

costs of TB diagnosis and treatment were estimated to be $20.7 (95% uncertainty interval: 12.8–

31.2) billion for DS-TB and $19.2 (15.6–23.1) billion for RR-TB (Appendix S5). For the infant

vaccine scenario, vaccine introduction costs were $11.8 (9.6–16.9) billion, and averted TB

diagnosis and treatment costs were $342 (223–489) million for DS-TB and $299 (251–351)

million for RR-TB over 2028–2050 (Appendix S6). For the adolescent/adult vaccine scenario,

vaccine introduction costs were $50.5 (38.1–75.9) billion, and averted TB diagnosis and

treatment costs were $3.5 (2.2–5.2) billion for DS-TB and $3.2 (2.6–3.8) billion for RR-TB over

2028–2050 (Appendix S7)—greater than the averted disease costs in the infant vaccine scenario.

There would also be $13.4 (9.5–19.2) million and $362 (281–466) million in additional ART

costs under the infant and adolescent/adult vaccine scenarios, respectively, due to extended

survival among people living with HIV (Appendices S8–S9).

There was greater, and more rapid, impact from an adolescent/adult vaccine compared to an

infant vaccine over the study period (Appendices S10–S11). Across 2028–2050, infant vaccine

costs were projected to increase smoothly from the year of vaccine introduction, whereas the

adolescent/adult vaccine scenario required major upfront investments during vaccine

introduction and 5-year campaign roll-out, then decreased substantially after campaigns were

completed.

In the base-case analysis, from the health system perspective, we found that infant vaccination

would be cost-effective (ICER below 1-times per-capita GDP) compared to no vaccination in 47

of 105 modelled LMICs (45%) and 24 of 27 with high-TB burden (89%). Using the same

assumptions, we found that adolescent/adult vaccination would be cost-effective in 64 out of 105

countries (61%) and all 27 with high-TB burden. Neither vaccine strategy would be cost-saving

in any country. Figure 1 displays the distribution of country-level cost-effectiveness results from

the health system perspective for infant and adolescent/adult vaccines, stratified by TB incidence

level. Vaccine introduction was more likely to be cost-effective in countries with higher TB

incidence.

From the societal perspective, the infant vaccine was cost-effective in 56 out of 105 countries

(53%), including all with high-TB burden, and cost-saving in 46 countries (44%). Similarly, the

adolescent/adult vaccine was cost-effective in 73 out of 105 countries (70%), remaining cost-

effective in all with high-TB burden, and cost-saving in 58 countries (55%). Figure 2 displays

the percentage of the modelled population that live in countries where vaccination was cost-

effective based on different cost-effectiveness thresholds (Appendix S12 shows the percentage of

countries where vaccination was cost-effective; Appendices S13–S14 present tabular results).

Tables 2 and 3 report summary health outcomes, costs, and cost-effectiveness of the base-case

vaccination scenarios. Across all 105 analyzed countries, the majority of TB cost-savings

accrued in high-TB-burden settings, particularly in lower middle-income settings and WHO

African region (AFR) and South-East Asian region (SEAR). Assuming 0% discounting on health

outcomes decreased ICERs (indicating greater cost-effectiveness) for the infant vaccine by

approximately 76% and for the adolescent/adult vaccine by approximately 69% from the health

system perspective (Appendices S15–S16).

*Return on investment*

With each averted DALY valued at per-capita GDP and costs assessed from the societal

perspective, we estimated a cumulative $68.6 (range: $44.5–100 across examined thresholds)

billion incremental net monetary benefit (iNMB) globally for infant vaccine introduction in

countries where introduction was cost-effective at 1-times per-capita GDP (Figure 3; tabular

results in Appendix S17). For the adolescent/adult vaccine, we estimated iNMB of $372 billion

for countries in which vaccination was cost-effective (range: $283–474 billion). These benefits

were concentrated in regions (AFR, SEAR) with higher disease burden. For the infant vaccine,

the market size (i.e., the vaccinated population in countries in which the vaccine would be cost-

effective at per-capita GDP from the societal perspective) would be 1.431 (1.430–1.432) billion

individuals, while for the adolescent/adult vaccine this population size would be 5.182 (5.180–

5.183) billion individuals. Under a more restrictive assumption where the vaccine is only

introduced in countries where the societal ICER is cost-saving, the market size would be 1.316

(1.315–1.317) billion individuals for the infant vaccine, and 4.642 (4.617–4.644) billion

individuals for the adolescent/adult vaccine. The largest markets were in the WHO SEAR and

WPR regions (Appendices S18–S19).

*Sensitivity analysis*

From both health system and societal perspectives, DALYs averted and costs decreased in the

low-coverage scenario, and increased in the high-coverage scenario, for both the infant and the

adolescent/adult vaccine, with evidence of diminishing returns as coverage increases

(Appendices S20–S23).

Compared to the base-case vaccination introduction and delivery scenario, the accelerated scale-

up scenario had greater health impact (DALYs averted) and better cost-effectiveness (assuming

per-unit vaccination costs were unchanged), with vaccination being cost-effective in all 105

LMICs for both the infant and adolescent/adult vaccine compared to a per-capita GDP threshold

(Appendices S24–S27). Conversely, the routine-only scenario had a much smaller health impact

and modestly worse cost-effectiveness profile, as compared to the base-case analysis (Appendix

S28).

Reducing the vaccine price by half decreased infant vaccination costs from $11.8 to $7.6 billion

(36% decrease) and adolescent/adult vaccination costs from $50.5 to $36.4 billion (28%

decrease; Appendices S29–S38). Doubling the vaccine price increased infant vaccination costs to

$20.2 billion (71% increase) and adolescent/adult vaccination costs to $78.8 billion (56%

increase). Switching to high-middle-tier vaccine pricing (higher vaccine prices for middle-

income countries) increased infant vaccine costs to $16.9 billion (44% increase) and

adolescent/adult vaccination costs to $72.1 billion (a 43% increase). From the health system

perspective, reducing the vaccine price by half increased the number of countries in which infant

vaccination was cost-effective at a per-capita GDP threshold from 47 to 51, whereas doubling

the vaccine price decreased the number of cost-effective countries to 32. Assuming higher

vaccine prices for middle-income countries reduced the number of countries in which the infant

vaccine was cost-effective at a per-capita GDP threshold from 47 to 41. Similarly, the half-price

scenario, double-price scenario, and high-middle-tier-price scenario changed the number of

countries in which the adolescent/adult vaccine was considered cost-effective from the health

system perspective at a per-capita GDP threshold from 64 in the base-case, to 70, 52, and 55,

respectively.

Assuming a two-dose vaccination course increased infant vaccination costs to $23.3 billion

(Appendix S29) and adolescent/adult vaccination costs to $100 billion (Appendix S30). From the

health system perspective, a two-dose vaccination course decreased the number of countries in

which infant vaccination was cost-effective at a per-capita GDP threshold from 47 to 31 and in

which adolescent/adult vaccination was cost-effective from 64 to 46 (Appendices S39–S40).

Assuming the no-new-vaccine baseline with faster incidence reductions through strengthening of

current TB interventions to meet the 2025 End TB targets, a number of countries remained cost-

saving from the societal perspective (9 countries for infant vaccine and 20 countries for

adolescent/adult vaccine; Appendices S41–S42).

An infant vaccine with lifelong duration of protection averted 30.0 (26.1–34.5) million DALYs,

a 66% increase compared to the base-case assumption of 10-year protection (Appendix S43). An

adolescent/adult vaccine with lifelong duration of protection averted 138 (127–150) million

DALYs (46% greater than the base-case; Appendix S44). Both vaccine products remained cost-

saving from the societal perspective; assuming lifelong duration of protection decreased the

ICER by approximately 42% and 36% for the infant and adolescent/adult vaccine, respectively

(health system perspective).

An adolescent/adult vaccine with 75% efficacy also averted 138 (127–150) million DALYs

(45% greater than the base-case; Appendix S45), but decreased the ICER to a greater degree than

lifelong duration of protection at 53%.

**Discussion**

An effective novel TB vaccine would offer large potential health and economic benefits over

2028–2050. The results of this analysis demonstrate that, when available, TB vaccines could be

cost-effective in a majority of LMICs, particularly from the societal perspective, and in

essentially all high-burden countries. Introducing novel TB vaccines could also offer high value

in terms of incremental net monetary benefit to patients, the health system, and society,

particularly in countries with high burden of TB, HIV-associated TB, and/or multidrug-

resistant/RR-TB.

For both vaccine product profiles, vaccination was more likely to be cost-effective in lower

middle-income countries (relative to low-income and upper middle-income countries), as

countries in this income group are more likely to have both significant TB burden and sufficient

economic resources to justify additional TB investments without displacing other important

health interventions. Vaccination was more frequently cost-effective in AFR and SEAR regions

and the adolescent/adult vaccine was estimated to be cost-effective in all countries in the 27

modelled high-TB burden countries that accounted for 81.8% of global incident TB cases and

80.9% of global TB deaths in 2020 [9, 13]. This relationship of ICERs decreasing as disease

burden increases has also been shown for several licensed vaccines, including HPV, malaria, and

rotavirus [34-36]. Although vaccines can be economically less viable for manufacturers, we

estimated large potential markets for vaccinees in high-burden, middle-income settings. We

estimated cost-effectiveness using a range of cost-effectiveness benchmarks, based on recent

discussion of the validity of conventional standards [31, 37-39]. Cost-effectiveness was stronger

in analyses that discounted future costs but not future health outcomes. Final decisions about

vaccine adoption will be made by local decision-makers, based on the values placed on health

benefits, opportunity costs, the relative timing of health outcomes and costs, and other context-

specific considerations.

There was greater, and more rapid, impact from an adolescent/adult vaccine over the 2028–2050

time horizon compared to an infant vaccine, as this vaccine is targeted to a population with the

highest burden of TB, and the delay between vaccination and TB prevention impact is shorter

with the adolescent/adult vaccine. For the adolescent/adult vaccine, we estimated major short-

term costs from introduction and one-time vaccination campaigns, with the highest costs

incurred during the ten years following vaccine introduction. In contrast, the cost-savings from

averted TB disease were realized gradually over 2028–2050, growing in magnitude towards the

end of the time horizon. By assuming the no-new-vaccine baseline meeting the End TB targets,

the remaining TB burden that could be averted by vaccination was estimated to be smaller,

yielding results that were less cost-effective.

There are several factors that distinguish this analysis from past studies [40-43]: firstly, the steps

taken to construct a realistic vaccine adoption timeline, based on an analysis of factors affecting

country adoption decisions and stakeholder consultation. As a result, this analysis provides a

more robust estimate of the potential timing of vaccine impact compared to past analyses, which

is particularly important given the expected role of vaccines in contributing to the attainment of

TB elimination targets for specific calendar years. Secondly, this study examined a wide range of

scenarios for vaccine introduction, illustrating how the pace and extent of scale-up affect overall

impact by 2050. In particular, the comparison of the base-case scenario to an accelerated scale-

up scenario demonstrates the additional health and economic gains that would be possible with

more rapid vaccine introduction. Thirdly, this study estimated incremental net monetary benefit

as a single measure summarizing the health and economic benefits of TB vaccine introduction.

Combined with the large number of countries modelled, this analysis quantifies the overall

global benefits of TB vaccination in a way that can be set against the costs and other challenges

that must be overcome to develop a new vaccine. This is particularly important for justifying the

investments that still need to be made in vaccine development and preparation for deployment.

This analysis had several limitations. We were constrained by data availability, with only 105

countries successfully parameterized and calibrated. However, these 105 countries represent

93.3% of LMIC TB incidence and 93.6% of LMIC TB mortality globally in 2020 [13]. As a

"pre- and post-infection" vaccine, the adolescent/adult vaccine was assumed to be equally

effective regardless of previous infection status, which may have led to an overestimation of

averted TB cases and deaths if the vaccine is less effective in infected vaccinees. We also

restricted the analysis to focus on vaccine products that would prevent development of TB

disease, and did not examine the possible impact of vaccine products that would prevent

infection, such as recombinant BCG vaccines [44]. If successfully developed, such vaccines

could provide another effective tool for accelerating TB control. We also extrapolated from

published literature [16-18] for several major unit cost inputs, potentially omitting important

country-level heterogeneity in these costs. The sample size of patient cost

surveys used for non-medical and productivity costs was small (20); therefore, the extrapolation

to other country settings may not capture the level of potential variation in these costs. We did

not investigate targeting high-risk subgroups for vaccination; vaccination could still be cost-

effective when targeted to subgroups in settings where vaccination was not estimated to be cost-

effective in a national roll-out. In our main analysis we used 1x per-capita GDP as a threshold to

approximate willingness-to-pay per DALY averted, based on its historical broad utilization in

economic evaluation studies. However, recent evidence suggests that a more stringent cost-

effectiveness threshold may be appropriate [30, 31], in which case vaccination would be cost-

effective in fewer countries, and estimates of return on investment would be lower. Finally, we

did not consider all possible product and introduction scenarios, such as varying ages of

vaccination, vaccine coverage targets, and scale-up trends by country, but demonstrated the

potential value of novel TB vaccines according to specified characteristics. Future work

developing detailed country-level models could take into account the health system capacity of

each country and the underlying country-specific TB epidemiology by age to inform more

realistic delivery scenarios.

354 Across this analysis, introduction of a novel TB vaccine was found to be impactful and cost-

355 effective for a range of assumptions on vaccine price and delivery strategies, with aggregate

356 health and economic benefits of similar scale to the most influential health interventions in

357 LMIC settings in recent years [45]. TB vaccines are still under development, so their potential

358 effectiveness and impact are uncertain. Accelerating the timeline for vaccine introduction,

359 decreasing the vaccine price, or increasing vaccine efficacy could all impact the cost-

360 effectiveness profile of vaccination and increase the magnitude of the benefits, directly

361 improving the welfare of individuals and households which would otherwise experience the

362 health and economic consequences of TB in coming years. Future work should investigate

363 country-level vaccine policy questions to support introduction preparedness. The results of these

364 analyses can be used by global and country stakeholders to inform these questions, as well as

365 decision-making around future development, adoption, and implementation of novel TB

366 vaccines.

**Acknowledgements**

This is part of a WHO commissioned work on the full value assessment of TB vaccines (2020/985800-0). We thank all the attendees at the WHO meetings on the Full Value Assessment of TB Vaccines for insightful advice and direction.

**Ethics approval and consent to participate**

Not applicable.

**Author contributions**

AP, NAM, RGW, MQ, and MJ conceptualized and designed the study. AP conducted the analysis with support from NAM, RAC, MQ, MJ, CKW, CM, AKD, and RGW. AP, NAM, RAC, and RGW drafted the initial manuscript and approved the final manuscript as submitted. MQ, CKW, CM, RB, AKD, SM, NG, MZ, SYS, RH, IGB, NN, and MJ critically reviewed the analysis, reviewed and revised the manuscript, and approved the final manuscript as submitted. All authors read and approved the final manuscript.

**Table 1. Unit cost inputs by country income level.**

| | LIC | LMIC | UMIC |
|---|---|---|---|
| Drug-susceptible TB diagnostics costs | 21.67 (17.55, 26.47) | 50.27 (40.71, 61.42) | 66.87 (54.15, 81.7) |
| Rifampicin-resistant TB diagnostics costs | 430.16 (349.13, 524.53) | 404.51 (327.57, 494.20) | 343.73 (278.35, 419.95) |
| Drug-susceptible TB treatment costs | 59.00 (37.14, 87.62) | 90.65 (53.37, 141.09) | 151.02 (85.28, 240.34) |
| Rifampicin-resistant TB treatment costs | 1538.09 (1309.96, 1798.54) | 3631.83 (3269.94, 4033.66) | 3974.10 (3593.33, 4395.81) |
| ART costs | 210.47 (204.30, 216.70) | 321.08 (310.26, 331.93) | 509.96 (488.81, 532.07) |
| Direct non-medical costs for drug-susceptible TB | 343.17 (327.55, 359.71) | 343.90 (327.08, 361.52) | 500.59 (468.36, 535.26) |
| Income loss experienced by patients during drug-susceptible TB care | 343.48 (327.22, 360.71) | 342.85 (325.97, 360.54) | 500.59 (468.36, 535.26) |
| Direct non-medical costs for rifampicin-resistant TB | 1373.14 (1293.92, 1459.45) | 1397.84 (1309.87, 1492.72) | 2240.79 (2057.04, 2450.43) |
| Income loss experienced by patients during rifampicin-resistant TB care | 1380.06 (1281.06, 1466.81) | 1393.65 (1305.31, 1488.93) | 2240.79 (2057.04, 2450.43) |
| Infant vaccine delivery costs | 1.61 (0.51, 3.96) | 2.89 (1.08, 6.51) | 4.61 (1.78, 10.64) |
| Adolescent/adult vaccine delivery costs | 3.05 (1.50, 5.68) | 3.25 (1.62, 6.27) | 3.80 (1.24, 9.50) |

Note: Values in parentheses represent equal-tailed 95% credible intervals. Low-income (LIC): Gross national income (GNI) per capita of $1,085 or less; Lower middle-income (LMIC): GNI per capita of $1,086 to $4,225; Upper middle-income (UMIC): GNI per capita of $4,256 to $13,205 (World Bank 2021).

**Table 2. Discounted costs, disability-adjusted life-years (DALYs) averted, and cost-effectiveness of infant tuberculosis vaccines**

| Country grouping | Health system perspective[a] incremental cost (USD billions) | Societal perspective[b] incremental cost (USD billions) | DALYs averted (millions) | Health system cost (USD) per DALY averted | Societal cost (USD) per DALY averted |
|---|---|---|---|---|---|
| All countries | 7.67 (6.25, 10.6) | *-27.4 (-32.6, -22.3)* | 18.0 (15.6, 20.8) | 428 (331, 606) | cost-saving[c] |
| High-TB burden[d] | 5.15 (4.26, 7.14) | *-28.1 (-33.1, -23.3)* | 16.6 (14.2, 19.5) | 311 (241, 443) | cost-saving[c] |
| High-TB/HIV burden[d] | 3.62 (3.03, 4.88) | *-24.9 (-29.9, -20.5)* | 14.5 (12.2, 17.3) | 251 (194, 350) | cost-saving[c] |
| High-MDR/RR-TB burden[d] | 4.53 (3.72, 6.33) | *-26.5 (-31.4, -21.7)* | 14.7 (12.4, 17.4) | 311 (236, 449) | cost-saving[c] |
| **Income level[e]** | | | | | |
| LIC | 1.12 (0.96, 1.44) | *-0.19 (-0.48, 0.15)* | 2.02 (1.70, 2.46) | 558 (431, 737) | cost-saving (cost-saving, 77.2) |
| LMIC | 3.95 (3.31, 5.31) | *-23.1 (-27.8, -18.8)* | 14.9 (12.6, 17.6) | 268 (208, 374) | cost-saving[c] |
| UMIC | 2.60 (1.96, 4.12) | *-4.15 (-6.24, -2.25)* | 1.12 (0.85, 1.50) | 2380 (1490, 3870) | cost-saving[c] |
| **World region** | | | | | |
| AFR | 2.40 (2.05, 3.13) | *-13.4 (-17.1, -10.4)* | 9.34 (7.72, 11.3) | 260 (196, 352) | cost-saving[c] |
| AMR | 0.69 (0.52, 1.07) | 0.29 (0.10, 0.67) | 0.06 (0.05, 0.08) | 10900 (7680, 16900) | 4630 (1400, 10700) |
| EMR | 1.05 (0.86, 1.42) | *-0.62 (-1.32, -0.01)* | 1.64 (1.15, 2.25) | 661 (430, 1010) | cost-saving[c] |
| EUR | 0.43 (0.30, 0.72) | 0.20 (0.07, 0.49) | 0.04 (0.03, 0.04) | 11100 (7530, 18900) | 5260 (1690, 12900) |
| SEAR | 1.59 (1.31, 2.18) | *-9.90 (-12.9, -7.37)* | 5.50 (4.15, 7.31) | 296 (204, 450) | cost-saving[c] |
| WPR | 1.50 (1.16, 2.33) | *-4.03 (-5.74, -2.62)* | 1.42 (1.04, 1.95) | 1080 (688, 1770) | cost-saving[c] |

[a] Costs from the health system perspective include vaccination costs, tuberculosis testing and treatment costs, and antiretroviral treatment costs.

[b] Costs from the societal perspective include health system perspective costs, as well as patient non-medical costs and productivity losses.

[c] Both the point estimate and the interval estimates are cost-saving.

[d] High-TB, high-TB/HIV (HIV-associated TB), and high-MDR/RR-TB (multidrug/rifampicin-resistant TB) burden countries as defined by the World Health Organization [9].

[e] LIC: Gross national income (GNI) per capita of $1,085 or less; LMIC: GNI per capita of $1,086 to $4,225; UMIC: GNI per capita of $4,256 to $13,205 (World Bank 2021).

Note: All countries include 105 low- and middle-income countries analyzed. Values in parentheses represent equal-tailed 95% credible intervals. AFR = African region; AMR = Region of the Americas; EMR = Eastern Mediterranean region; EUR = European region; GDP = gross domestic product; LIC = low-income; LMIC = lower middle-income; SEAR = Southeast Asian region; UMIC = upper middle-income; USD = United States dollar; WPR = Western Pacific region.

**Table 3. Discounted costs, disability-adjusted life-years (DALYs) averted, and cost-effectiveness of adolescent/adult tuberculosis vaccines**

| Country grouping | Health system perspective[a] incremental cost (USD billions) | Societal perspective[b] incremental cost (USD billions) | Incremental DALYs averted (millions) | Health system cost (USD) per DALY averted | Societal cost (USD) per DALY averted |
|---|---|---|---|---|---|
| All countries | 36.3 (26.8, 55.2) | *-145 (-165, -123)* | 94.8 (86.9, 103) | 383 (276, 579) | cost-saving[c] |
| High-TB burden[d] | 26.0 (19.0, 39.8) | *-142 (-159, -122)* | 86.5 (78.5, 95.1) | 301 (213, 462) | cost-saving[c] |
| High-TB/HIV burden[d] | 15.8 (11.8, 22.9) | *-131 (-147, -115)* | 77.1 (69.6, 85.3) | 205 (148, 299) | cost-saving[c] |
| High-MDR/RR-TB burden[d] | 24.0 (17.2, 37.5) | *-133 (-151, -114)* | 76.9 (69.2, 85.3) | 312 (217, 486) | cost-saving[c] |
| **Income level[e]** | | | | | |
| LIC | 3.73 (2.98, 4.98) | *-2.57 (-3.70, -1.20)* | 9.53 (8.40, 10.7) | 394 (301, 535) | cost-saving[c] |
| LMIC | 17.1 (13.0, 24.3) | *-119 (-133, -105)* | 78.2 (70.8, 86.3) | 219 (160, 317) | cost-saving[c] |
| UMIC | 15.5 (10.1, 27.4) | *-24.0 (-33.8, -9.93)* | 7.15 (5.89, 8.83) | 2190 (1320, 4140) | cost-saving[c] |
| **World region** | | | | | |
| AFR | 6.89 (5.51, 9.26) | *-56.6 (-66.4, -48.3)* | 38.9 (35.0, 42.8) | 178 (137, 246) | cost-saving[c] |
| AMR | 3.84 (2.60, 6.56) | *-0.17 (-1.54, 2.67)* | 0.73 (0.65, 0.81) | 5300 (3510, 9050) | cost-saving (cost-saving, 3590) |
| EMR | 4.06 (3.19, 5.61) | *-2.65 (-4.45, -0.70)* | 6.61 (5.22, 8.24) | 623 (438, 908) | cost-saving[c] |
| EUR | 2.08 (1.40, 3.56) | *-0.64 (-1.41, 0.82)* | 0.50 (0.45, 0.56) | 4130 (2730, 7260) | cost-saving (cost-saving, 1710) |
| SEAR | 9.38 (7.01, 13.6) | *-71.3 (-82.6, -59.8)* | 41.7 (35.8, 48.3) | 226 (159, 338) | cost-saving[c] |
| WPR | 10.0 (6.55, 17.6) | *-13.8 (-18.5, -5.79)* | 6.37 (5.55, 7.31) | 1580 (1000, 2810) | cost-saving[c] |

[a] Costs from the health system perspective include vaccination costs, tuberculosis testing and treatment costs, and antiretroviral treatment costs.

[b] Costs from the societal perspective include health system perspective costs, as well as patient non-medical costs and productivity losses.

[c] Both the point estimate and the interval estimates are cost-saving.

[d] High-TB, high-TB/HIV (HIV-associated TB), and high-MDR/RR-TB (multidrug/rifampicin-resistant TB) burden countries as defined by the World Health Organization [9].

[e] LIC: Gross national income (GNI) per capita of $1,085 or less; LMIC: GNI per capita of $1,086 to $4,225; UMIC: GNI per capita of $4,256 to $13,205 (World Bank 2021).

Note: All countries include 105 low- and middle-income countries analyzed. Values in parentheses represent equal-tailed 95% credible intervals. AFR = African region; AMR = Region of the Americas; EMR = Eastern Mediterranean region; EUR = European region; GDP = gross domestic product; LIC = low-income; LMIC = lower middle-income; SEAR = Southeast Asian region; UMIC = upper middle-income; USD = United States dollar; WPR = Western Pacific region.

**Figure 1. Cost-effectiveness results from the health system perspective for novel tuberculosis vaccines by country and vaccine.**

Note: Points represent each of 105 low- and middle-income countries analyzed in the base-case scenario, stratified by tuberculosis incidence per 100,000. Line represents a cost-effectiveness threshold of 1x per-capita GDP in 2020. Vaccine introduction would be considered cost-effective for countries falling underneath this line. DALY = disability-adjusted life year; GDP = gross domestic product.

**Figure 2. Percentage of population that live in countries where vaccination was cost-effective compared to percentage of gross domestic product per capita thresholds, comparing health system and societal perspectives.**

Note: Countries include 105 low- and middle-income countries analyzed. Population includes vaccinated individuals 2028–2050. Gross domestic product per capita estimates from 2020. GDP = gross domestic product per capita.

**Figure 3. Incremental net monetary benefit of novel tuberculosis vaccines assessed from the societal perspective, for several willingness-to-pay thresholds.**

Note: Estimates include the incremental net monetary benefit from the countries that are cost-effective at the respective threshold [29-31]. Gross domestic product per capita estimates from 2020. GDP = gross domestic product per capita.

## References

1. World Health Organization. Global Tuberculosis Report 2021. Geneva: World Health Organization. 14 October 2021. https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2021 (accessed 1 December 2021).
2. World Health Organization. The End TB Strategy. Geneva: World Health Organization. 16 August 2015. https://www.who.int/teams/global-tuberculosis-programme/the-end-tb-strategy (accessed 1 July 2021).
3. Silva S, Arinaminpathy N, Atun R, Goosby E, Reid M. Economic impact of tuberculosis mortality in 120 countries and the cost of not achieving the Sustainable Development Goals tuberculosis targets: a full-income analysis. Lancet Glob Health. 2021;9(10):e1372-e9.
4. Tait DR, Hatherill M, Van Der Meeren O, Ginsberg AM, Van Brakel E, Salaun B, et al. Final Analysis of a Trial of M72/AS01(E) Vaccine to Prevent Tuberculosis. N Engl J Med. 2019;381(25):2429-39.
5. Hutubessy R, Lauer JA, Giersing B, Sim SY, Jit M, Kaslow D, et al. The Full Value of Vaccine Assessments (FVVA): A Framework to Assess and Communicate the Value of Vaccines for Investment and Introduction Decision Making. 7 May 2021. http://dx.doi.org/10.2139/ssrn.3841999 (accessed 27 May 2021).
6. Gebreselassie N, Hutubessy R, Vekemans J, den Boon S, Kasaeva T, Zignol M. The case for assessing the full value of new tuberculosis vaccines. Eur Respir J. 2020;55(3).
7. Clark RA, Mukandavire C, Portnoy A, Weerasuriya CK, Deol A, Scarponi D, et al. The impact of alternative delivery strategies for novel tuberculosis vaccines in low- and middle-income countries: a modelling study. medRxiv; 2022. doi: https://doi.org/10.1101/2022.04.16.22273762.
8. World Bank. World Bank Country and Lending Groups. Washington, DC: The World Bank; 2021. https://datahelpdesk.worldbank.org/knowledgebase/articles/906519 (accessed 12 September 2022).
9. World Health Organization. WHO releases new global lists of high-burden countries for TB, HIV-associated TB and drug-resistant TB. 17 June 2021. https://www.who.int/news/item/17-06-2021-who-releases-new-global-lists-of-high-burden-countries-for-tb-hiv-associated-tb-and-drug-resistant-tb (accessed 1 July 2021).
10. World Health Organization. WHO Preferred Product Characteristics for New Tuberculosis Vaccines. Geneva: World Health Organization. Licence: CC BY-NC-SA 3.0 IGO. 13 July 2018. https://www.who.int/publications/i/item/WHO-IVB-18.06 (accessed 18 October 2021).
11. World Health Organization. WHO-UNICEF estimates of DTP3 coverage: monitoring system 2019 global summary. Geneva: WHO/UNICEF. 15 July 2020. http://apps.who.int/immunization_monitoring/globalsummary/timeseries/tswucoveragedtp3.html (accessed 20 April 2021).
12. Harris RC, Sumner T, Knight GM, Zhang H, White RG. Potential impact of tuberculosis vaccines in China, South Africa, and India. Sci Transl Med. 2020;12(564).
13. World Health Organization. WHO TB Burden Estimates. Geneva: World Health Organization. 14 October 2021. https://www.who.int/tb/country/data/download/en/ (accessed 17 December 2021).
14. Salomon JA, Haagsma JA, Davis A, de Noordhout CM, Polinder S, Havelaar AH, et al. Disability weights for the Global Burden of Disease 2013 study. Lancet Glob Health. 2015;3(11):e712-23.

15. Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2019 (GBD 2019) Reference Life Table. Seattle, United States of America: Institute for Health Metrics and Evaluation (IHME). 5 January 2021. https://doi.org/10.6069/1D4Y-YQ37 (accessed 17 February 2021).

16. Laurence YV, Griffiths UK, Vassall A. Costs to Health Services and the Patient of Treating Tuberculosis: A Systematic Literature Review. Pharmacoeconomics. 2015;33(9):939-55.

17. Siapka M, Vassall A, Cunnama L, Pineda C, Cerecero D, Sweeney S, et al. Cost of tuberculosis treatment in low- and middle-income countries: systematic review and meta-regression. Int J Tuberc Lung Dis. 2020;24(8):802-10.

18. van den Hof S, Collins D, Hafidz F, Beyene D, Tursynbayeva A, Tiemersma E. The socioeconomic impact of multidrug resistant tuberculosis on patients: results from Ethiopia, Indonesia and Kazakhstan. BMC Infect Dis. 2016;16(1):470.

19. Global Health Cost Consortium. Unit Cost Study Repository, Version 5.0. 8 May 2020. https://ghcosting.org/pages/data/ucsr/app/ (accessed 3 February 2021).

20. World Health Organization. Tuberculosis patient cost surveys: a hand book. Geneva: World Health Organization. 2 November 2017. https://www.who.int/publications/i/item/9789241513524 (accessed 23 March 2021).

21. World Health Organization. National surveys of costs faced by TB patients and their households, 2015-2021. Geneva: 2022. In press (2022).

22. Portnoy A, Yamanaka T, Nguhiu P, Nishikiori N, Floyd K, Baena IG, et al. The patient costs of TB treatment in low- and middle-income countries: a meta-regression analysis of 20 nationally-representative patient cost surveys.

23. International Monetary Fund. World Economic Outlook Database, October 2021. Last updated: 1 July 2021. [Online] Accessed 12 April 2022. Available at: https://www.imf.org/en/Publications/WEO/weo-database/2021/October.

24. World Bank. World development indicators. Washington, DC: The World Bank; 2020. Last updated: 8 April 2022. [Online] Accessed 12 April 2022. Available at: http://data.worldbank.org/.

25. UNICEF. Vaccines pricing data. 8 March 2022. https://www.unicef.org/supply/vaccines-pricing-data (accessed 17 March 2022).

26. UNICEF. Costs of Vaccinating a Child. 14 August 2020. https://immunizationeconomics.org/recent-activity/2021/6/15/standard-costs-of-vaccinating-a-child (accessed 20 January 2021).

27. Portnoy A, Vaughan K, Clarke-Deelder E, Suharlim C, Resch SC, Brenzel L, et al. Producing Standardized Country-Level Immunization Delivery Unit Cost Estimates. Pharmacoeconomics. 2020;38(9):995-1005.

28. Gavi The Vaccine Alliance. GAVI Alliance Vaccine Introduction Grant and Operational Support for Campaigns Policy. Version No. 1.0. Geneva: Gavi, The Vaccine Alliance. 2 April 2013. www.gavi.org (accessed 12 July 2018).

29. World Bank. World development indicators. Washington, DC: The World Bank; 2021. http://data.worldbank.org/ (accessed 19 January 2022).

30. Ochalek J, Lomas J, Claxton K. Estimating health opportunity costs in low-income and middle-income countries: a novel approach and evidence from cross-country data. BMJ Glob Health. 2018;3(6):e000964.

31. Woods B, Revill P, Sculpher M, Claxton K. Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research. Value Health. 2016;19(8):929-35.

32. Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. Clin Ther. 2022;44(2):158-68.

33. Briggs AH, Weinstein MC, Fenwick EA, Karnon J, Sculpher MJ, Paltiel AD. Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--6. Value Health. 2012;15(6):835-42.

34. Janko MM, Joffe J, Michael D, Earl L, Rosettie KL, Sparks GW, et al. Cost-effectiveness of rotavirus vaccination in children under five years of age in 195 countries: A meta-regression analysis. Vaccine. 2022;40(28):3903-17.

35. Rosettie KL, Joffe JN, Sparks GW, Aravkin A, Chen S, Compton K, et al. Cost-effectiveness of HPV vaccination in 195 countries: A meta-regression analysis. PLoS One. 2021;16(12):e0260808.

36. Sauboin C, Van Bellinghen LA, Van De Velde N, Van Vlaenderen I. Economic Impact of Introducing the RTS,S Malaria Vaccine: Cost-Effectiveness and Budget Impact Analysis in 41 Countries. MDM Policy Pract. 2019;4(2):2381468319873324.

37. Loganathan T, Ng CW, Lee WS, Hutubessy RCW, Verguet S, Jit M. Thresholds for decision-making: informing the cost-effectiveness and affordability of rotavirus vaccines in Malaysia. Health Policy Plan. 2018;33(2):204-14.

38. Thokala P, Ochalek J, Leech AA, Tong T. Cost-Effectiveness Thresholds: the Past, the Present and the Future. Pharmacoeconomics. 2018;36(5):509-22.

39. Jit M. Informing Global Cost-Effectiveness Thresholds Using Country Investment Decisions: Human Papillomavirus Vaccine Introductions in 2006-2018. Value Health. 2021;24(1):61-6.

40. Knight GM, Griffiths UK, Sumner T, Laurence YV, Gheorghe A, Vassall A, et al. Impact and cost-effectiveness of new tuberculosis vaccines in low- and middle-income countries. Proc Natl Acad Sci U S A. 2014;111(43):15520-5.

41. Fu H, Lewnard JA, Frost I, Laxminarayan R, Arinaminpathy N. Modelling the global burden of drug-resistant tuberculosis avertable by a post-exposure vaccine. Nat Commun. 2021;12(1):424.

42. Weerasuriya CK, Harris RC, McQuaid CF, Bozzani F, Ruan Y, Li R, et al. The epidemiologic impact and cost-effectiveness of new tuberculosis vaccines on multidrug-resistant tuberculosis in India and China. BMC Med. 2021;19(1):60.

43. Bishai DM, Mercer D. Modeling the economic benefits of better TB vaccines. Int J Tuberc Lung Dis. 2001;5(11):984-93.

44. Cotton MF, Madhi SA, Luabeya AK, Tameris M, Hesseling AC, Shenje J, et al. Safety and immunogenicity of VPM1002 versus BCG in South African newborn babies: a randomised, phase 2 non-inferiority double-blind controlled trial. Lancet Infect Dis. 2022;22(10):1472-83.

45. The Global Fund. Fight for What Counts: The Global Fund Investment Case. Seventh Replenishment 2022. 23 February 2022. https://www.theglobalfund.org/en/fight-for-what-counts/ (accessed 16 March 2022).